Cargando…
Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades
Pregnancy-associated osteoporosis (PAO) is a rare syndrome which typically presents with vertebral fractures during pregnancy or lactation. The medical records of sixteen patients with PAO who presented to a specialist clinic at the Western General Hospital in Edinburgh over a 20-year period were re...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673946/ https://www.ncbi.nlm.nih.gov/pubmed/37819437 http://dx.doi.org/10.1007/s00223-023-01139-3 |
_version_ | 1785140729724534784 |
---|---|
author | Orhadje, Elizabeth Berg, Kathryn Hauser, Barbara Ralston, Stuart H. |
author_facet | Orhadje, Elizabeth Berg, Kathryn Hauser, Barbara Ralston, Stuart H. |
author_sort | Orhadje, Elizabeth |
collection | PubMed |
description | Pregnancy-associated osteoporosis (PAO) is a rare syndrome which typically presents with vertebral fractures during pregnancy or lactation. The medical records of sixteen patients with PAO who presented to a specialist clinic at the Western General Hospital in Edinburgh over a 20-year period were reviewed to evaluate the mode of presentation, potential risk factors and response to treatment. The most common presentation was back pain occurring in 13/16 (81.2%) individuals due to multiple vertebral fractures. The diagnosis was usually made postpartum and in 12/16 individuals (75.0%), PAO presented during the woman’s first pregnancy. Medicines which could have contributed to the development of PAO included thromboprophylaxis therapies in 8 subjects (50.0%), inhaled or injected corticosteroids in 5 (31.3%), anticonvulsants in 2 (12.5%) and a LHRH agonist in 1 (6.3%). Five individuals reported a family history of osteoporosis, and two pregnancies were complicated by hyperemesis gravidarum. Treatments administered included calcium and vitamin D supplements, bisphosphonates and teriparatide. Bone mineral density increased following the diagnosis in all cases, regardless of treatment given. One patient had further fracture during follow-up, but four patients had subsequent pregnancies without fractures. We estimated that in this locality, the incidence of PAO was 6.8/100,000 pregnancies with a point prevalence of 4.1 per 100,000 women. This case series indicates the importance of family history of osteoporosis and thromboprophylaxis drugs as risk factors for PAO while also demonstrating that the reductions in bone density tend to reverse with time, irrespective of the treatment given. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00223-023-01139-3. |
format | Online Article Text |
id | pubmed-10673946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-106739462023-10-11 Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades Orhadje, Elizabeth Berg, Kathryn Hauser, Barbara Ralston, Stuart H. Calcif Tissue Int Original Research Pregnancy-associated osteoporosis (PAO) is a rare syndrome which typically presents with vertebral fractures during pregnancy or lactation. The medical records of sixteen patients with PAO who presented to a specialist clinic at the Western General Hospital in Edinburgh over a 20-year period were reviewed to evaluate the mode of presentation, potential risk factors and response to treatment. The most common presentation was back pain occurring in 13/16 (81.2%) individuals due to multiple vertebral fractures. The diagnosis was usually made postpartum and in 12/16 individuals (75.0%), PAO presented during the woman’s first pregnancy. Medicines which could have contributed to the development of PAO included thromboprophylaxis therapies in 8 subjects (50.0%), inhaled or injected corticosteroids in 5 (31.3%), anticonvulsants in 2 (12.5%) and a LHRH agonist in 1 (6.3%). Five individuals reported a family history of osteoporosis, and two pregnancies were complicated by hyperemesis gravidarum. Treatments administered included calcium and vitamin D supplements, bisphosphonates and teriparatide. Bone mineral density increased following the diagnosis in all cases, regardless of treatment given. One patient had further fracture during follow-up, but four patients had subsequent pregnancies without fractures. We estimated that in this locality, the incidence of PAO was 6.8/100,000 pregnancies with a point prevalence of 4.1 per 100,000 women. This case series indicates the importance of family history of osteoporosis and thromboprophylaxis drugs as risk factors for PAO while also demonstrating that the reductions in bone density tend to reverse with time, irrespective of the treatment given. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00223-023-01139-3. Springer US 2023-10-11 2023 /pmc/articles/PMC10673946/ /pubmed/37819437 http://dx.doi.org/10.1007/s00223-023-01139-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Orhadje, Elizabeth Berg, Kathryn Hauser, Barbara Ralston, Stuart H. Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title | Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title_full | Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title_fullStr | Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title_full_unstemmed | Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title_short | Clinical Features, Incidence and Treatment Outcome in Pregnancy-Associated Osteoporosis: A Single-Centre Experience over Two Decades |
title_sort | clinical features, incidence and treatment outcome in pregnancy-associated osteoporosis: a single-centre experience over two decades |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673946/ https://www.ncbi.nlm.nih.gov/pubmed/37819437 http://dx.doi.org/10.1007/s00223-023-01139-3 |
work_keys_str_mv | AT orhadjeelizabeth clinicalfeaturesincidenceandtreatmentoutcomeinpregnancyassociatedosteoporosisasinglecentreexperienceovertwodecades AT bergkathryn clinicalfeaturesincidenceandtreatmentoutcomeinpregnancyassociatedosteoporosisasinglecentreexperienceovertwodecades AT hauserbarbara clinicalfeaturesincidenceandtreatmentoutcomeinpregnancyassociatedosteoporosisasinglecentreexperienceovertwodecades AT ralstonstuarth clinicalfeaturesincidenceandtreatmentoutcomeinpregnancyassociatedosteoporosisasinglecentreexperienceovertwodecades |